Patents Assigned to Inhibitex, Inc.
-
Patent number: 9351989Abstract: This invention is directed to phosphoroamidate and phosphorodiamidate derivatives including the compounds of formula (I) having the structure wherein U, V, W, Z, R1, X1, X2, and Y are defined herein. These compounds and pharmaceutical compositions containing these compounds are useful in the treatment of viral infections in mammals infected by a virus in the Flaviviridae family of viruses, in particular hepatitis C virus (HCV). The compounds of this invention may be prepared by various methods known in the art of organic chemistry in general and nucleoside and nucleotide analog synthesis in particular.Type: GrantFiled: December 29, 2011Date of Patent: May 31, 2016Assignees: INHIBITEX, INC., UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITEDInventors: Chris McGuigan, Karolina Madela, Claire Bourdin, John Vernachio, Stanley Chamberlain
-
Patent number: 9296795Abstract: Immunogenic polysaccharide-protein conjugates having a polysaccharide antigen (or its oligosaccharide fragment representing one or more antigenic epitopes) derived from a nosocomial pathogen conjugated to a staphylococcal surface adhesin carrier protein are used in immunogenic compositions to elicit antibody responses to both the polysaccharide antigen and the staphylococcal surface adhesion carrier protein. Such immunogenic compositions are used to immunize against diseases caused by Staphylococcal aureus, Staphylococcal epidermidis or other nosocomial pathogens.Type: GrantFiled: March 4, 2004Date of Patent: March 29, 2016Assignees: WYETH HOLDINGS, LLC., INHIBITEX, INC.Inventors: Viliam Pavliak, Steven Morris Baker, Subramonia Padmanaba Pillai
-
Publication number: 20140286903Abstract: This invention is directed to compounds of Formula (I) having the structure that are useful in the treatment of viral infections in mammals, particularly in humans, mediated, at least in part, by a virus in the Flaviviridae family of viruses.Type: ApplicationFiled: November 8, 2012Publication date: September 25, 2014Applicants: INHIBITEX, INC., UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITEDInventors: Stanley Chamberlain, John Vernachio, Srinivas K. Battina, Changalvala V.S. Ramamurty, C. Srinivas Rao, Chris McGuigan, Andrea Brancale
-
Patent number: 8759318Abstract: Phosphoramidate compounds derived from guanine bases having enhanced therapeutic potency are provided, and these compounds in particular have enhanced potency with respect to treatment of viral infections, such as hepatitis C virus. Pharmaceutical compositions, methods of preparing the compounds, and methods of using the compounds and compositions to treat viral infections are also provided.Type: GrantFiled: January 11, 2010Date of Patent: June 24, 2014Assignees: Inhibitex, Inc., University College Cardiff Consultants LimitedInventors: Stanley Chamberlain, Jeff Hutchins, Karolina Madela, Christopher McGuigan, John Vernachio, Mohamed Aljarah, Arnaud Gilles
-
Publication number: 20140140955Abstract: This invention is directed to novel compounds of formula (I) having the structure (I) wherein U, V, W, Z, R1, X1, X2, and Y are defined herein. The compounds of formula (I) and pharmaceutical compositions containing these compounds are useful in the treatment of viral infections in mammals mediated, at least in part, by a virus in the Flaviviridae family of viruses, in particular hepatitis C virus (HCV).Type: ApplicationFiled: December 29, 2011Publication date: May 22, 2014Applicants: UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED, INHIBITEX, INC.Inventors: Chris McGuigan, Karolina Madela, Claire Bourdin, John Vernachio, Stanley Chamberlain
-
Patent number: 8475798Abstract: Monoclonal antibodies which can bind to the SdrF protein of Staphylococcus epidermidis are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus epidermidis. The monoclonal antibodies of the invention are advantageous in that they can also recognize binding domains and subdomains of the S. epidermidis SdrF protein in addition to the protein itself. Suitable compositions and passive vaccines based on the monoclonal antibodies of the invention, as well as methods for their use, are also provided.Type: GrantFiled: June 16, 2006Date of Patent: July 2, 2013Assignees: Inhibitex, Inc., The Texas A&M University SystemInventors: Joseph M. Patti, Jeff T. Hutchins, Andrea Hall, Linda Santos, Maria Bowden, Magnus Hook
-
Patent number: 7968100Abstract: Surface proteins are provided which generate polyclonal and monoclonal antibodies which are cross-reactive to both coagulase-positive staphylococcus bacteria, such as S. aureus and to coagulase-negative bacteria, such as S. epidermidis and S. hemolyticus. The antibodies may be generated from surface proteins that have been isolated on the basis of characteristics that may be common between S. aureus and coagulase-negative staphylococci, or the A domains of those surface proteins, and these recombinant surface proteins are used to generate the cross-reactive antibodies. Vaccines comprising an immunologically effective amount of the proteins are also provided, and these vaccines are used in methods for the treatment or protection against a wide variety of staphylococcal infections.Type: GrantFiled: February 4, 2009Date of Patent: June 28, 2011Assignees: Universita'Degli Studi Di Pavia, Inhibitex, Inc., Provost Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth Near DublinInventors: Timothy Foster, Fiona Roche, Mark Pallen, Joseph M. Patti, Jeff T. Hutchins, Pietro Speziale
-
Patent number: 7850974Abstract: A bioinformatic method for identifying and isolating proteins and peptides with MSCRAMM®-like characteristics from Gram positive bacteria, such as Enterococcus, Staphylococcus, Streptococcus and Bacillus bacteria, and proteins and peptides obtained thereby are provided which can be utilized in methods to prevent and treat infections caused by Gram-positive bacteria. The method involves identifying from sequence information those proteins with a putative C-terminal LPXTG (SEQ ID NO:1) cell wall sorting signal and other structural similarities to MSCRAMM® proteins having the LPXTG-anchored cell wall proteins. The MSCRAMM® proteins and immunogenic regions therein that are identified and isolated using the present invention may be useful in the diagnosis, treatment or prevention of Gram positive bacterial infections.Type: GrantFiled: October 8, 2009Date of Patent: December 14, 2010Assignees: The Texas A&M University System, Inhibitex, Inc., The UAB Research FoundationInventors: Magnus Hook, Yi Xu, Jouko V. Sillanpaa, Narayana Sthanam, Karthe Ponnuraj, Joseph M. Patti, Jeff T. Hutchins, Andrea Hall, Maria G. Bowden
-
Patent number: 7666438Abstract: Multicomponent vaccines are provided which aid in the prevention and treatment of staphylococcal infections and which include certain selected combinations of bacterial binding proteins or fragments thereof, or antibodies to those proteins or fragments. By careful selection of the proteins, fragments, or antibodies, a vaccine is provided that imparts protection against a broad spectrum of Staphylococcus and other bacterial strains and against proteins that are expressed at different stages of the logarithmic growth curve. In one embodiment of the invention, a composition is provided that includes a fibrinogen binding domain of a fibrinogen binding protein and a bacterial component such as ca capsular polysaccharide, and both active and passive vaccines based on these components are also provided, along with methods of treating infection using these compositions and vaccines.Type: GrantFiled: March 9, 2004Date of Patent: February 23, 2010Assignees: Inhibitex, Inc., The Provost Fellows and Scholars of the College of the Holy and Undivived Trinity of Queen Elizabeth Near Dublin, The Texas A&M University SystemInventors: Joseph M. Patti, Timothy J. Foster, Magnus Hook
-
Patent number: 7615616Abstract: A bioinformatic method is provided for identifying and isolating proteins with MSCRAMM®—like characteristics from Gram positive bacteria, such as Enterococcus, Staphylococcus, Streptococcus and Bacillus bacteria, which can then be utilized in methods to prevent and treat infections caused by Gram-positive bacteria. The method involves identifying from sequence information those proteins with a putative C-terminal LPXTG (SEQ ID NO:1) cell wall sorting signal and other structural similarities to MSCRAMM® proteins having the LPXTG-anchored cell wall proteins. The MSCRAMM® proteins and immunogenic regions therein that are identified and isolated using the present invention may be used to generate antibodies useful in the diagnosis, treatment or prevention of Gram positive bacterial infections.Type: GrantFiled: September 15, 2003Date of Patent: November 10, 2009Assignees: The Texas A&M University System, Inhibitex, Inc., The UAB Research FoundationInventors: Magnus Hook, Yi Xu, Jouko V. Sillanpaa, Narayana Sthanam, Karthe Ponnuraj, Joseph M. Patti, Jeff T. Hutchins, Andrea Hall, Maria G. Bowden
-
Patent number: 7381793Abstract: Isolated extracellular matrix-binding proteins, designated ClfB, SdrC, SdrD and SdrE, and their corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials. ClfB is a cell-wall associated protein having a predicted molecular weight of approximately 88 kDa and an apparent molecular weight of approximately 124 kDa, which binds both soluble and immobilized fibrinogen.Type: GrantFiled: December 24, 2003Date of Patent: June 3, 2008Assignees: Inhibitex, Inc., BioResearch Ireland, The Texas A&M University SystemInventors: Joseph M. Patti, Timothy J. Foster, Elisabet Josefsson, Deidre Ni Eidhin, Magnus A. O. Hook, Samuel E. Perkins
-
Patent number: 7364738Abstract: Monoclonal antibodies which can bind to the ClfA protein and which are generated from binding subdomains or active fragments of the ClfA protein from Staphylococcus aureus, including the active fragments proteins from its fibrinogen binding domain such as Clf40 protein, the Clf33 protein, or ClfA N3, are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus aureus. In addition, medical instruments can be treated using the monoclonal antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the antibodies of the present invention are advantageous because they can prevent adherence of the bacteria to host cells by impairing or inhibiting the ability of S. aureus ClfA to bind to fibrinogen or fibrin, and thus can be utilized in methods or treating or preventing staphylococcal inventions.Type: GrantFiled: May 25, 2005Date of Patent: April 29, 2008Assignee: Inhibitex, Inc.Inventors: Joseph M. Patti, Jeff T. Hutchins, Paul Domanski, Pratiksha Patel, Andrea Hall
-
Patent number: 7241592Abstract: Antibodies to the CNA protein and to other regions from the collagen binding domain, including domain CNA19, are provided, and antibodies produced in this manner have been shown to be cross reactive to both Staphylococcus aureus and Staphylococcus epidermidis bacteria and which can thus be used in the prevention and treatment of infections caused by both of these types of bacteria. In addition, medical instruments can be treated using the antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the proteins are advantageous because they are cross-reactive and may thus be administered to patients so as to reduce or prevent severe infection by staphylococcal bacteria of more than one species.Type: GrantFiled: March 19, 2001Date of Patent: July 10, 2007Assignees: Universita Degli Studi di Pavia, The Texas A&M University System, Inhibitex, Inc.Inventors: Magnus Hook, Yi Xu, Pietro Speziale, Livia Visal, Fabrizia Casolini, Joseph M. Patti, Pratiksha Patel, Paul Domanski
-
Publication number: 20070141077Abstract: Immunogenic polysaccharide-protein conjugates having a polysaccharide antigen (or its oligosaccharide fragment representing one or more antigenic epitopes) derived from a nosocomial pathogen conjugated to a staphylococcal surface adhesin carrier protein are used in immunogenic compositions to elicit antibody responses to both the polysaccharide antigen and the staphylococcal surface adhesin carrier protein. Such immunogenic compositions are used to immunize against diseases caused by Staphylococcal aureus, Staphylococcal epidermidis or other nosocomial pathogens.Type: ApplicationFiled: November 7, 2006Publication date: June 21, 2007Applicants: Wyeth Holdings Corporation, Inhibitex, Inc.Inventors: Viliam Pavliak, Steven Baker, Subramonia Pillai, Joseph Patti, Bradley Prater
-
Publication number: 20070087014Abstract: Immunogenic polysaccharide-protein conjugates having a polysaccharide antigen (or its oligosaccharide fragment representing one or more antigenic epitopes) derived from a nosocomial pathogen conjugated to a staphylococcal surface adhesin carrier protein are used in immunogenic compositions to elicit antibody responses to both the polysaccharide antigen and the staphylococcal surface adhesion carrier protein. Such immunogenic compositions are used to immunize against diseases caused by Staphylococcal aureus, Staphylococcal epidermidis or other nosocomial pathogens.Type: ApplicationFiled: March 4, 2004Publication date: April 19, 2007Applicants: Wyeth, Inhibitex, Inc.Inventors: Viliam Pavliak, Steven Baker, Subramonia Pillai, Joseph Patti, Bradley Prater
-
Publication number: 20070026011Abstract: An isolated and/or purified Sdr surface protein from S. capitis and nucleic acids encoding them are provided which includes the SdrX protein which possesses collagen binding activites and the SdrZL protein which possesses SdrZ-like properties. The Sdr surface proteins from S. capitis can be used in pharmaceutical compositions to treat and prevent S. capitis infectionm and can also be used in vaccines and to raise antibodies which can treat or prevent such infections. Because the SdrX protein has been shown to have collagen binding abilities, antibodies to SdrX will have the ability to inhibit or prevent the ability of S. capitis to bind to collagen.Type: ApplicationFiled: June 1, 2004Publication date: February 1, 2007Applicant: INHIBITEX, INC.Inventors: Yule Liu, John Vernachio, Joseph Patti
-
Patent number: 7045131Abstract: A method and composition for the passive immunization of patients infected with or susceptible to infection from Staphylococcus bacteria such as S. aureus and S. epidermidis infection is provided that includes the selection or preparation of a donor plasma pool with high antibody titers to carefully selected Staphylococcus adhesins or MSCRAMMs, or fragments or components thereof, or sequences with substantial homology thereto. The donor plasma pool can be prepared by combining individual blood or blood component samples which have higher than normal titers of antibodies to one or more of the selected adhesins or other proteins that bind to extracellular matrix proteins, or by administering carefully selected proteins or peptides to a host to induce the expression of desired antibodies, and subsequently recovering the enhanced high titer serum or plasma pool from the treated host.Type: GrantFiled: March 7, 2002Date of Patent: May 16, 2006Assignee: Inhibitex, Inc.Inventors: Joseph M. Patti, Timothy J. Foster, Magnus Hook
-
Patent number: 6979446Abstract: Monoclonal antibodies which can bind to the ClfA protein and which are generated from binding subdomains or active fragments of the ClfA protein from Staphylococcus aureus, including the active fragments proteins from its fibrinogen binding domain such as Clf40 protein, the Clf33 protein, or ClfA N3, are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus aureus. In addition, medical instruments can be treated using the monoclonal antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the antibodies of the present invention are advantageous because they can prevent adherence of the bacteria to host cells by impairing or inhibiting the ability of S. aureus ClfA to bind to fibrinogen or fibrin, and thus can be utilized in methods or treating or preventing staphylococcal inventions.Type: GrantFiled: January 28, 2002Date of Patent: December 27, 2005Assignee: Inhibitex, Inc.Inventors: Joseph M. Patti, Jeff T. Hutchins, Paul Domanski, Pratiksha Patel, Andrea Hall
-
Patent number: 6841154Abstract: Polyclonal and monoclonal antibodies which are cross-reactive to both coagulase-positive staphylococcus bacteria, such as S. aureus and to coagulase-negative bacteria, such as S. epidermidis and S. hemolyticus, are provided which can recognize surface proteins from both coagulase-positive and coagulase negative staph bacteria. The antibodies may be generated from surface proteins that have been isolated on the basis of characteristics that may be common between S. aureus and coagulase-negative staphylococci, and these recombinant surface proteins are used to generate the antibodies of the invention. There is also provided vaccines and methods which utilize these proteins and antibodies for the treatment or protection against a wide variety of staphylococcal infections.Type: GrantFiled: June 17, 2002Date of Patent: January 11, 2005Assignees: Inhibitex, Inc., The Provost Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin, Universita'degli Studi di PaviaInventors: Timothy Foster, Fiona Roche, Mark Pallen, Joseph M. Patti, Jeff T. Hutchins, Pietro Speziale
-
Patent number: 6703025Abstract: Multicomponent vaccines are provided which aid in the prevention and treatment of staphylococcal infections and which include certain selected combinations of bacterial binding proteins or fragments thereof, or antibodies to those proteins or fragments. By careful selection of the proteins, fragments, or antibodies, a vaccine is provided that imparts protection against a broad spectrum of Staphylococcus bacterial strains and against proteins that are expressed at different stages of the logarithmic growth curve. In one embodiment of the invention, a composition is provided that includes at least a collagen binding protein or peptide (or an appropriate site directed mutated sequence thereof) such as CNA, or a protein or fragment with sufficiently high homology thereto, in combination with a fibrinogen binding protein, preferably Clumping factor A (“ClfA”) or Clumping factor B (“ClfB”), or a useful fragment thereof or a protein or fragment with sufficiently high homology thereto.Type: GrantFiled: August 31, 1999Date of Patent: March 9, 2004Assignees: Inhibitex, Inc., The Provost Fellows and Scholars of the College of The Holy and Undivided Trinity of Queen Elizabeth near Dublin, The Texas A&M University SystemInventors: Joseph M. Patti, Timothy J. Foster, Magnus Hook